This is the authors' abstract. We don't add key points for this paper.
SbnE is an essential enzyme for staphyloferrin B biosynthesis in Staphylococcus aureus . An earlier study showed that natural product baulamycin A has in vitro inhibitory activity against SbnE and antibacterial potency. A SAR study with analogues of baulamycin A was conducted to identify potent inhibitors of SbnE and/or effective antibiotics against MRSA . The results show that selected analogues, including 11 , 18 , 21 , 24a , 24c , 24m and 24n , exhibit single-digit micromolar inhibitory potencies against SbnE (IC 50 s = 1.81–8.94 μM) and 11 , 24m , 24n possess significant activities against both SbnE (IC 50 s = 4.12–6.12 μM) and bacteria (MICs = 4–32 μg/mL). Biological investigations revealed that these substances possess potent cell wall disruptive activities and that they inhibit siderophore production in MRSA . Among the selected analogues, 7 has excellent antibiotic activities both gram-positive and –negative bacteria (0.5–4 μg/mL). Moreover, these analogues significantly impede biofilm formation in a concentration-dependent manner. Taken together, the results of the investigation provide valuable insight into the nature of novel baulamycin A analogues that have potential efficacy against MRSA owing to their membrane damaging activity and/or inhibitory efficacy against siderophore production.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: